Literature DB >> 17357126

Clinical and imaging evidence of zolpidem effect in hypoxic encephalopathy.

Christine Brefel-Courbon1, Pierre Payoux, Fabierine Ory, Agnes Sommet, Tarik Slaoui, Gaelle Raboyeau, Beatrice Lemesle, Michele Puel, Jean-Louis Montastruc, Jean-Francois Demonet, Dominique Cardebat.   

Abstract

We conducted a randomized, double-blind, placebo-controlled, single-patient (N = 1) trial to evaluate the efficacy of zolpidem in a 48-year-old woman with an akinetic mutism. Motor and cognitive examinations and functional imaging were performed. Acute administration of zolpidem markedly improved motor performance and neuropsychological status. Cerebral metabolism ((18)F-fluorodeoxyglucose positron emission tomography) increased in postrolandic territories and in frontal cortex. Using the H(2) (15)O positron emission tomography, we found a drug-induced activation in the anterior cingulate and orbitofrontal cortices. Zolpidem induced a transient improvement in motor and cognitive performances. This paradoxical effect could result from an activation of limbic loops modulating motivational processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17357126     DOI: 10.1002/ana.21110

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  36 in total

Review 1.  What is the role of brain mechanisms underlying arousal in recovery of motor function after structural brain injuries?

Authors:  Andrew M Goldfine; Nicholas D Schiff
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

Review 2.  Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?

Authors:  Rosella Ciurleo; Placido Bramanti; Rocco Salvatore Calabrò
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  Catatonia after cerebral hypoxia: do the usual treatments apply?

Authors:  Davin K Quinn; Christopher C Abbott
Journal:  Psychosomatics       Date:  2014-03-27       Impact factor: 2.386

4.  α2-Adrenergic stimulation of the ventrolateral preoptic nucleus destabilizes the anesthetic state.

Authors:  Hilary S McCarren; Michael R Chalifoux; Bo Han; Jason T Moore; Qing Cheng Meng; Nina Baron-Hionis; Madineh Sedigh-Sarvestani; Diego Contreras; Sheryl G Beck; Max B Kelz
Journal:  J Neurosci       Date:  2014-12-03       Impact factor: 6.167

5.  GABAA receptor deficits predict recovery in patients with disorders of consciousness: A preliminary multimodal [(11) C]Flumazenil PET and fMRI study.

Authors:  Pengmin Qin; Xuehai Wu; Niall W Duncan; Weiqi Bao; Weijun Tang; Zhengwei Zhang; Jin Hu; Yi Jin; Xing Wu; Liang Gao; Lu Lu; Yihui Guan; Timothy Lane; Zirui Huang; Yelena G Bodien; Joseph T Giacino; Ying Mao; Georg Northoff
Journal:  Hum Brain Mapp       Date:  2015-07-03       Impact factor: 5.038

6.  Arterial spin labeling and altered cerebral blood flow patterns in the minimally conscious state.

Authors:  A A Liu; H U Voss; J P Dyke; L A Heier; N D Schiff
Journal:  Neurology       Date:  2011-09-21       Impact factor: 9.910

7.  Potential network mechanisms mediating electroencephalographic beta rhythm changes during propofol-induced paradoxical excitation.

Authors:  Michelle M McCarthy; Emery N Brown; Nancy Kopell
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

Review 8.  Recovery of consciousness after brain injury: a mesocircuit hypothesis.

Authors:  Nicholas D Schiff
Journal:  Trends Neurosci       Date:  2009-12-01       Impact factor: 13.837

Review 9.  Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem.

Authors:  Romy Hoque; Andrew L Chesson
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

Review 10.  Disorders of consciousness after acquired brain injury: the state of the science.

Authors:  Joseph T Giacino; Joseph J Fins; Steven Laureys; Nicholas D Schiff
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.